[go: up one dir, main page]

DE602007006671D1 - Verwendung von nnmt als marker für lungenkrebs - Google Patents

Verwendung von nnmt als marker für lungenkrebs

Info

Publication number
DE602007006671D1
DE602007006671D1 DE602007006671T DE602007006671T DE602007006671D1 DE 602007006671 D1 DE602007006671 D1 DE 602007006671D1 DE 602007006671 T DE602007006671 T DE 602007006671T DE 602007006671 T DE602007006671 T DE 602007006671T DE 602007006671 D1 DE602007006671 D1 DE 602007006671D1
Authority
DE
Germany
Prior art keywords
lung cancer
nnmt
marker
assessment
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007006671T
Other languages
English (en)
Inventor
Wolfgang Rollinger
Marie-Luise Hagmann
Johann Karl
Theresa Kott
Markus Roessler
Michael Tacke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Original Assignee
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Roche Diagnostics GmbH filed Critical F Hoffmann La Roche AG
Publication of DE602007006671D1 publication Critical patent/DE602007006671D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G01N33/5752—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602007006671T 2006-08-01 2007-07-30 Verwendung von nnmt als marker für lungenkrebs Active DE602007006671D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06015951 2006-08-01
PCT/EP2007/006713 WO2008014951A1 (en) 2006-08-01 2007-07-30 Use of nnmt as a marker for lung cancer

Publications (1)

Publication Number Publication Date
DE602007006671D1 true DE602007006671D1 (de) 2010-07-01

Family

ID=37078767

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007006671T Active DE602007006671D1 (de) 2006-08-01 2007-07-30 Verwendung von nnmt als marker für lungenkrebs

Country Status (9)

Country Link
US (1) US7785821B2 (de)
EP (1) EP2049905B1 (de)
JP (1) JP4981133B2 (de)
CN (1) CN101495870B (de)
AT (1) ATE468535T1 (de)
CA (1) CA2655851A1 (de)
DE (1) DE602007006671D1 (de)
ES (1) ES2345167T3 (de)
WO (1) WO2008014951A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2297581B1 (de) 2008-07-03 2013-04-03 F. Hoffmann-La Roche AG Asc als lungenkrebsmarker
JP5976694B2 (ja) * 2011-03-11 2016-08-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 慢性閉塞性肺疾患（ｃｏｐｄ）のマーカーとしてのｎｎｍｔ
EP2684052B1 (de) * 2011-03-11 2016-04-27 Roche Diagniostics GmbH Apex1 als marker für die chronisch obstruktive lungenerkrankung (copd)
CN102435748B (zh) * 2011-11-25 2014-07-16 广东药学院 一种双抗夹心酶联免疫检测试剂盒及其制备方法
CN102618501A (zh) * 2011-12-26 2012-08-01 浙江大学 Nnmt蛋白单克隆抗体、杂交瘤细胞株及应用
US20160369349A1 (en) * 2013-06-28 2016-12-22 Eiken Kagaku Kabushiki Kaisha Novel lung cancer biomarker (liph)
CN106248946A (zh) * 2016-08-19 2016-12-21 浙江大学 一种酶联免疫检测试剂盒及其应用
EP4278186A1 (de) * 2021-01-14 2023-11-22 F. Hoffmann-La Roche AG Prognostischer wert von biomarkern bei patienten mit nicht-kleinzelligem lungenkrebs mit stabiler erkrankung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3691798B2 (ja) * 2002-02-18 2005-09-07 三洋化成工業株式会社 血液中の腫瘍マーカー定量方法
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
CN100437115C (zh) * 2002-12-20 2008-11-26 霍夫曼-拉罗奇有限公司 烟酰胺n-甲基转移酶作为结肠直肠癌标志的用途
ES2325277T3 (es) * 2004-12-23 2009-08-31 F. Hoffmann-La Roche Ag Uso de cyfra 21-1 y osteopontina, como marcadores para el cancer colorrectal.
CA2705486C (en) * 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
EP2071337A1 (de) * 2007-12-10 2009-06-17 F.Hoffmann-La Roche Ag Seprase als Krebsmarker

Also Published As

Publication number Publication date
WO2008014951A1 (en) 2008-02-07
CN101495870A (zh) 2009-07-29
EP2049905A1 (de) 2009-04-22
EP2049905B1 (de) 2010-05-19
CA2655851A1 (en) 2008-02-07
US7785821B2 (en) 2010-08-31
HK1136873A1 (en) 2010-07-09
ATE468535T1 (de) 2010-06-15
US20090263841A1 (en) 2009-10-22
ES2345167T3 (es) 2010-09-16
JP4981133B2 (ja) 2012-07-18
JP2009545731A (ja) 2009-12-24
CN101495870B (zh) 2013-09-04

Similar Documents

Publication Publication Date Title
ATE554389T1 (de) Apex als marker für lungenkrebs
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
SG10201408392PA (en) Methods of determining patient response by measurement of her-3
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
BRPI0814202A2 (pt) Métodos e sistemas de determinação de concentração de produto de análise em amostra fluida e meio legível em computador
MX2015016047A (es) Metodo y sistema para mantener o mejorar el bienestar.
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
WO2010046443A3 (en) Methods for detection and diagnosis of a bone or cartilage disorder
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
EA201391627A1 (ru) Анализ на наличие лизилоксидазоподобных белков 2 и способы его применения
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
ATE531822T1 (de) Diagnose von prostatakrebs
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
ATE359516T1 (de) Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs
ATE529745T1 (de) Verfahren zur bewertung des hautempfindlichkeitsniveaus durch verwendung von mit plattenepithelkarzinom zusammenhängendem antigen als indikation
ATE393393T1 (de) Verwendung des proteins spee als marker für brustkrebs
DE602005014659D1 (de) Auf immunreaktion gegen boris basierendes verfahren für den nachweis von krebs
ATE418737T1 (de) Verwendung des proteins spermidinsynthase (spee) als marker für kolorektalkarzinom

Legal Events

Date Code Title Description
8364 No opposition during term of opposition